In reply

JAMA Neurology

Volumn 71, Issue 3, 2014, Pages 371-372

  Chatterjee, Saurav ^a   Sardar, Partha ^b   Biondi Zoccai, Giuseppe ^c   Kumbhani, Dharam J ^d  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b METROPOLITAN HOSPITAL CENTER   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ANALYTICAL ERROR; BAYES THEOREM; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DATA ANALYSIS; DRUG SURVEILLANCE PROGRAM; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); METHODOLOGY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SAMPLING; STATISTICAL ANALYSIS; TREATMENT DURATION; ANIMAL; CHEMICALLY INDUCED DISORDER; NOTE;

ANIMALS; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; INTRACRANIAL HEMORRHAGES;

EID: 84896745707     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.6003     Document Type: Letter

References (7)

1. Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol. 2013; 70(12): 1486-1490.
2. Ezekowitz MD, Bridgers SL, James KE, et al; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992; 327(20): 1406-1412.
3. Sardar P, Chatterjee S, Wu WC, et al. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLoS One. 2013; 8(10): e77694.
4. Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364(9): 806-817.
5. Dogliotti A, Paolasso E, Giugliano RP. Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients [published online September 5, 2013]. Heart. doi:10.1136/heartjnl-2013-304347.
6. Bloomfield HE, Krause A, Greer N, et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med. 2011; 154(7): 472-482.
7. Davidson T, Husberg M, Janzon M, Oldgren J, Levin LÅ. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. Eur Heart J. 2013; 34(3): 177-183.